{"id":"lenacapavir-long-acting","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4802249","moleculeType":"Small molecule","molecularWeight":"990.28"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lenacapavir targets the HIV capsid, a critical viral structure that protects the viral genome during early infection. By inhibiting capsid uncoating, the drug prevents the release of viral RNA into the host cell cytoplasm, thereby blocking reverse transcription and integration. This novel mechanism of action is distinct from existing antiretroviral classes and provides activity against drug-resistant HIV strains.","oneSentence":"Lenacapavir is a first-in-class HIV capsid inhibitor that binds to the HIV capsid protein and blocks the uncoating of viral RNA, preventing early steps of HIV replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:43.935Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-experienced adults with multidrug-resistant HIV-1"}]},"trialDetails":[{"nctId":"NCT07402044","phase":"","title":"CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)","status":"NOT_YET_RECRUITING","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2026-03-15","conditions":"CABOTEGRAVIR, LENACAPAVIR","enrollment":50},{"nctId":"NCT07497594","phase":"NA","title":"ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention","status":"RECRUITING","sponsor":"Oswaldo Cruz Foundation","startDate":"2026-02-03","conditions":"Contact With or Exposure to Human Immunodeficiency Virus","enrollment":1500},{"nctId":"NCT04150068","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2019-11-21","conditions":"HIV-1-infection","enrollment":72},{"nctId":"NCT04979728","phase":"","title":"HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-05-27","conditions":"HIV Treatment, HIV Prevention","enrollment":150},{"nctId":"NCT06101342","phase":"PHASE2","title":"Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-12-13","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":181},{"nctId":"NCT07218211","phase":"PHASE4","title":"Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-13","conditions":"HIV Prevention, HIV Pre-exposure Prophylaxis, HIV Prevention Program","enrollment":100},{"nctId":"NCT06657885","phase":"PHASE2","title":"CAbotégravir LENacapavir DUal Long Acting","status":"WITHDRAWN","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2025-01-15","conditions":"HIV1 Infection, Multi-treated Patients Who Have Received Multiple Lines of Antiretroviral Treatment, CABOTEGRAVIR","enrollment":""},{"nctId":"NCT04925752","phase":"PHASE3","title":"Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-06-28","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":3292},{"nctId":"NCT06749054","phase":"PHASE2","title":"Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-03-26","conditions":"HIV-1-infection","enrollment":12},{"nctId":"NCT06970223","phase":"PHASE1","title":"A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2025-04-22","conditions":"HIV Infections","enrollment":65},{"nctId":"NCT07210125","phase":"PHASE4","title":"Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting","status":"RECRUITING","sponsor":"Kelley-Ross & Associates, Inc.","startDate":"2025-09-16","conditions":"HIV","enrollment":75},{"nctId":"NCT06101329","phase":"PHASE2","title":"Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-11-17","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":253},{"nctId":"NCT06513312","phase":"PHASE2","title":"Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-07","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":268},{"nctId":"NCT04994509","phase":"PHASE3","title":"Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-08-30","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":5368},{"nctId":"NCT05729568","phase":"PHASE2","title":"A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-05-15","conditions":"HIV Infection","enrollment":83},{"nctId":"NCT04143594","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-11-22","conditions":"HIV-1-infection","enrollment":183}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":131,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Yeztugo","Lenacapavir injection","PrEP","Injectable PrEP"],"phase":"marketed","status":"active","brandName":"Lenacapavir long-acting","genericName":"Lenacapavir long-acting","companyName":"ViiV Healthcare","companyId":"viiv-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lenacapavir is a first-in-class HIV capsid inhibitor that binds to the HIV capsid protein and blocks the uncoating of viral RNA, preventing early steps of HIV replication. Used for HIV-1 infection in treatment-experienced adults with multidrug-resistant HIV-1.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}